14 completed, 7 terminated. 9 Phase 3, 8 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Terminated 6, Completed 3 |
| Phase 2 | 8 | Completed 7, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
Follow tabalumab: new trials by email Literature Review of tabalumab trials Research Report on tabalumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Tabalumab Auto-Injector, Tabalumab Prefilled Syringe - Lupus Erythematosus, Systemic | Phase 3 | Terminated | Eli Lilly and Company | 226 | 2014-01-01 | 2018-06-15 |
| Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA) Tabalumab Auto-Injector, Tabalumab Prefilled Syringe - Rheumatoid Arthritis | Phase 3 | Terminated | Eli Lilly and Company | 8 | 2012-09-01 | 2018-04-26 |
| A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) Placebo, Dexamethasone, Bortezomib - Multiple Myeloma | Phase 2 | Completed | Eli Lilly and Company | 220 | 2012-07-01 | 2019-10-08 |
| Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma Tabalumab, Bortezomib IV, Bortezomib SC - Multiple Myeloma | Phase 1 | Completed | Eli Lilly and Company | 16 | 2012-07-01 | 2019-03-20 |
| A Study of LY2127399 in Rheumatoid Arthritis LY2127399 - Rheumatoid Arthritis | Phase 2 | Terminated | Eli Lilly and Company | 2 | 2012-05-01 | 2018-04-26 |
| On Open-Label Study in Participants With Systemic Lupus Erythematosus LY2127399, Placebo - Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Terminated | Eli Lilly and Company | 1518 | 2012-01-01 | 2018-05-17 |
| An Open Label Study for Participants With Rheumatoid Arthritis LY2127399 - Rheumatoid Arthritis | Phase 3 | Terminated | Eli Lilly and Company | 1086 | 2011-06-01 | 2018-06-11 |
| A Study in Participants With End-Stage Renal Disease LY2127399 - Kidney Failure, Chronic | Phase 2 | Completed | Eli Lilly and Company | 18 | 2011-04-01 | 2018-05-14 |
| A Rheumatoid Arthritis Study in Participants LY2127399, Placebo - Rheumatoid Arthritis | Phase 3 | Completed | Eli Lilly and Company | 1004 | 2011-01-01 | 2018-04-25 |
| A Study of LY2127399 in Participants With Systemic Lupus Erythematosus LY2127399, Placebo every 2 weeks, Placebo every 4 weeks - Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Completed | Eli Lilly and Company | 1124 | 2011-01-01 | 2018-07-17 |
| A Study in Participants With Rheumatoid Arthritis LY2127399, Placebo Q4W, Placebo Q2W - Rheumatoid Arthritis | Phase 3 | Terminated | Eli Lilly and Company | 456 | 2011-01-01 | 2018-05-14 |
| A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate LY2127399, Placebo Q2W, Placebo Q4W - Rheumatoid Arthritis | Phase 3 | Terminated | Eli Lilly and Company | 1041 | 2010-12-01 | 2018-05-08 |
| A Study of LY2127399 in Participants With Systemic Lupus Erythematosus LY2127399, Placebo every 2 weeks, Placebo every 4 weeks - Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Completed | Eli Lilly and Company | 1164 | 2010-12-01 | 2018-06-12 |
| A Study of Japanese Rheumatoid Arthritis Participants LY2127399 - Rheumatoid Arthritis | Phase 1 | Completed | Eli Lilly and Company | 26 | 2010-05-01 | 2019-03-01 |
| A Study for Japanese Participants With Rheumatoid Arthritis (RA) LY2127399 (Tabalumab), Placebo - Rheumatoid Arthritis | Phase 1 | Completed | Eli Lilly and Company | 32 | 2009-09-01 | 2018-10-23 |
| A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) LY2127399, Placebo - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Completed | Eli Lilly and Company | 245 | 2009-04-01 | 2018-11-15 |
| An Open Label Extension Study in Participants With Rheumatoid Arthritis LY2127399 - Rheumatoid Arthritis | Phase 2 | Completed | Eli Lilly and Company | 182 | 2009-02-01 | 2018-04-25 |
| A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy LY2127399, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Eli Lilly and Company | 158 | 2008-10-01 | 2018-07-10 |
| A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy LY2127399, Placebo - Arthritis, Rheumatoid | Phase 2 | Completed | Eli Lilly and Company | 100 | 2008-06-01 | 2018-12-06 |
| A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib LY2127399 - Multiple Myeloma | Phase 1 | Completed | Applied Molecular Evolution | 48 | 2008-03-01 | 2015-06-29 |
Showing 20 of 21. Sign in to see all of them.
Arthritis, Rheumatoid (12) · Lupus Erythematosus, Systemic (4) · Autoimmune Diseases (3) · Connective Tissue Diseases (3) · Immune System Diseases (3) · Multiple Myeloma (3) · Arthritis (2) · Recurrence (2) · Kidney Failure, Chronic (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Sclerosis (1) · Uremia (1)
Eli Lilly and Company (20) · Applied Molecular Evolution (1)
United States (17) · Poland (11) · Mexico (9) · Argentina (8) · Germany (8) · Japan (8) · Romania (8) · Australia (7) · Brazil (7) · Hungary (7) · Russia (7) · South Korea (7) · India (6) · Taiwan (6) · Ukraine (6)
PMID 27220348, PMID 27723281, PMID 29045736, PMID 31790472, PMID 35947992, PMID 38676311, PMID 23268367, PMID 23359344, PMID 23599435, PMID 25168268, PMID 25873635, PMID 26293163, PMID 26338095, PMID 26535134, PMID 26780484, PMID 27350068, PMID 33687069